Source: http://www.google.com/patents/US8114395?ie=ISO-8859-1&dq=6985872
Timestamp: 2015-06-30 10:38:25
Document Index: 184415224

Matched Legal Cases: ['Application No. 2003248419', 'Application No. 2003248419', 'Application No. 2004279350', 'Application No. 2003248419', 'Application No. 2006257286', 'Application No. 200706014', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 2', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 200680007733', 'Application No. 200480031909', 'Application No. 200480031909', 'Application No. 200480031910', 'Application No. 200680007733', 'Application No. 01104367', 'Application No. 200480031909', 'Application No. 200480031910', 'Application No. 200680007733', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 01104367', 'Application No. 02702211', 'Application No. 02702211', 'Application No. 02702211', 'Application No. 04809634', 'Application No. 04782529', 'Application No. 279', 'Application No. 310', 'Application No. 00310', 'Application No. 1214', 'Application No. 00311', 'Application No. 00311', 'Application No. 280', 'Application No. 2002', 'Application No. 2006', 'Application No. 2006', 'Application No. 2006', 'Application No. 2002', 'Application No. 200601204', 'Application No. 200601204', 'Application No. 200706014', 'Application No. 95107930', 'Application No. 095107930', 'Application No. 92', 'Application No. 92', 'Application No. 92']

Patent US8114395 - Treatment of viral diseases with recombinant interferon α - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsThis invention provides a recombinant super-compound interferon or an equivalent thereof with changed spatial configuration. The super-compound interferon possesses anti-viral or anti-tumor activity and therefore is useful to prevent and treat viral diseases and cancers. This invention also provides...http://www.google.com/patents/US8114395?utm_source=gb-gplus-sharePatent US8114395 - Treatment of viral diseases with recombinant interferon αAdvanced Patent SearchPublication numberUS8114395 B2Publication typeGrantApplication numberUS 12/105,455Publication dateFeb 14, 2012Filing dateApr 18, 2008Priority dateFeb 28, 2001Also published asCA2439503A1, CN1245215C, CN1311035A, DE60234085D1, EP1371373A1, EP1371373A4, EP1371373B1, US7364724, US8425896, US20040202641, US20080305080, US20110189128, WO2002080958A1Publication number105455, 12105455, US 8114395 B2, US 8114395B2, US-B2-8114395, US8114395 B2, US8114395B2InventorsGuangwen Wei, Rongbing Guo, Renhuai ZhangOriginal AssigneeSichuan Biotechnology Research CenterExport CitationBiBTeX, EndNote, RefManPatent Citations (52), Non-Patent Citations (165), Classifications (22), Legal Events (2) External Links: USPTO, USPTO Assignment, EspacenetTreatment of viral diseases with recombinant interferon α
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4179337Jul 28, 1977Dec 18, 1979Davis Frank FNon-immunogenic polypeptidesUS4462940May 18, 1983Jul 31, 1984Cetus CorporationProcess for the recovery of human β-interferon-like polypeptidesUS4672108Jul 3, 1985Jun 9, 1987Hoffmann-La Roche Inc.Crystalline human leukocyte interferonUS4681930Aug 10, 1984Jul 21, 1987Hoffmann-La Roche Inc.Immune interferon and a method for its extraction and purificationUS4695623Dec 12, 1983Sep 22, 1987AmgenConsensus human leukocyte interferonUS4897471Sep 21, 1987Jan 30, 1990AmgenConsensus human leukocyte interferonUS5372808Apr 15, 1992Dec 13, 1994Amgen Inc.Methods and compositions for the treatment of diseases with consensus interferon while reducing side effectUS5441734Feb 25, 1993Aug 15, 1995Schering CorporationMetal-interferon-alpha crystalsUS5602232Dec 14, 1994Feb 11, 1997Schering CorporationMethod for producing metal-interferon-α crystalsUS5710027May 26, 1994Jan 20, 1998Boehringer Ingelheim International GmbhProcess and vector for expressing alpha-interferon in E. coliUS5874304Jan 18, 1996Feb 23, 1999University Of Florida Research Foundation, Inc.Humanized green fluorescent protein genes and methodsUS5972331Dec 22, 1995Oct 26, 1999Schering CorporationCrystalline interferon alpha for pulmonary delivery and method for producing the sameUS5980884Feb 5, 1996Nov 9, 1999Amgen, Inc.Methods for retreatment of patients afflicted with Hepatitis C using consensus interferonUS6087478Jan 23, 1998Jul 11, 2000The Rockefeller UniversityCrystal of the N-terminal domain of a STAT protein and methods of use thereofUS6114145Dec 2, 1998Sep 5, 2000Human Genome Sciences, Inc.Synferon, a synthetic interferonUS6532437Oct 23, 1996Mar 11, 2003Cornell Research Foundation, Inc.Crystalline frap complexUS6546074Mar 27, 2001Apr 8, 2003Astex Technology LimitedProtein crystal structure and method for identifying protein modulatorsUS6579695Oct 11, 1996Jun 17, 2003President And Fellows Of Harvard CollegePhosphopantetheinyl transferases and uses thereofUS7364724Aug 28, 2003Apr 29, 2008Sichuan Biotechnology Research CenterRecombinant super-compound interferonUS20020043262Aug 22, 2001Apr 18, 2002Alan LangfordSpray deviceUS20040115169Dec 31, 2003Jun 17, 2004Chiron CorporationMethods of protein purification and recoveryUS20040202641Aug 28, 2003Oct 14, 2004Sichuan Biotechnology Research CenterRecombinant super-compound interferonAU2003248419A1 Title not availableCN1062565CJun 29, 1998Feb 28, 2001深圳九先生物工程有限公司Recombinating haman alpha type composite interferon and preparation process and use thereofCN1098103CApr 15, 1993Jan 8, 2003安姆根有限公司Pharmaceutical use of sympathetic human white-cell interferonCN1099799AMay 26, 1994Mar 8, 1995贝林格尔-英格海姆国际有限公司Process for preparing and purifying alpha-interferonCN1120846AFeb 24, 1994Apr 17, 1996先灵公司Metal-interferon-alpha crystalsCN1186120ADec 24, 1996Jul 1, 1998深圳科兴生物制品有限公司Recombinative human interferon protein as secretory gene in colibacillusCN1217660AJan 13, 1997May 26, 1999安姆根有限公司Method for retreatment of patients afflicted with Hepatitis C using consensus interferonCN1256148ADec 6, 1999Jun 14, 2000天津华立达生物工程有限公司Stable water solution of interferonCN1291198AFeb 4, 1999Apr 11, 2001伊来克萨斯独资有限公司Three-dimesional structures and models of Fc receptors and use thereofCN1375502AOct 25, 2001Oct 23, 2002南京药科大学Polyglycol modified recombinant human interferonCN1384116AMay 16, 2002Dec 11, 2002中国人民解放军第二军医大学New-type alpha-interferonCN1478545AJul 18, 2003Mar 3, 2004中国科学院微生物研究所Use of compound interferon in the treating of SARS diseaseDE4329756A1Sep 3, 1993Mar 9, 1995Boehringer Ingelheim IntProcess for the preparation and purification of alpha-interferonEP0083734B1Dec 3, 1982Mar 5, 1986F. HOFFMANN-LA ROCHE &amp; CO. AktiengesellschaftCrystalline human leukocyte interferonEP0422697A1Apr 25, 1983Apr 17, 1991Amgen Inc.A consensus leukocyte interferon and a gene encoding itEP0736303B1Mar 30, 1996Aug 25, 1999F. Hoffmann-La Roche AgInterferon solutionEP0777495B1Oct 10, 1995Jul 19, 2000Schering CorporationStable, aqueous alfa interferon solution formulationsWO1983004053A1Apr 25, 1983Nov 24, 1983Applied Molecular Genetics IncThe manufacture and expression of large structural genesWO1993021229A1Apr 14, 1993Oct 28, 1993Amgen IncMethods and compositions for the treatment of diseases with interferon while reducing side effectsWO1994019373A1Feb 24, 1994Sep 1, 1994Schering CorpMetal-interferon-alpha crystalsWO1997013845A2Oct 11, 1996Apr 17, 1997Harvard CollegePhosphopantetheinyl transferases and uses thereofWO1997027866A1Jan 13, 1997Aug 7, 1997Amgen IncMethods for retreatment of patients afflicted with hepatitis c using consensus interferonWO1999040117A1Feb 4, 1999Aug 12, 1999Ilexus Pty LimitedTHREE-DIMENSIONAL STRUCTURES AND MODELS OF Fc RECEPTORS AND USES THEREOFWO2001035987A1Nov 17, 2000May 25, 2001Han KyuboemAn aqueous solution formulation of alpha-interferonWO2002036627A2Nov 5, 2001May 10, 2002Pbl Biomedical LabInterferons, uses and compositions related theretoWO2002080958A1Feb 28, 2002Oct 17, 2002Rongbing GuoRecombination super compound interferon used as hepatitis b surface antigen and e antigen inhibitorWO2005021777A2Aug 26, 2004Mar 10, 2005Huiyangtech Usa IncUses of spatial configuration to modulate protein functionWO2005034853A2Aug 26, 2004Apr 21, 2005Huiyangtech Usa IncUses of interferons with altered spatial structureWO2005067963A1Feb 24, 2004Jul 28, 2005Lawrence M BlattUse of polyethylene glycol-modified interferon-alpha in therapeutic dosing regimensWO2006134497A2Mar 9, 2006Dec 21, 2006Guangwen WeiUses of recombinant super-compound interferonsNon-Patent CitationsReference1Advisory Action Before the Filing of an Appeal Brief for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated May 22, 2007.2Advisory Action Before the Filing of an Appeal Brief, Jul. 17, 2008, for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005.3Advisory Action before the Filing of an Appeal Brief, U.S. Appl. No. 10/928,474, filed Aug. 28, 2003, Dated Mar. 18, 2008.4Alton, K. et al., 1983, "Production, characterization and biological effects of recombinant DNA derived human IFN-α and IFN-γ analogs." In: De Maeger E, Schellekens H. eds. The Biology of Interferon System 2nd ed. Amsterdam: Elsevier Science Publishers, p. 119-128.5Amato, Ivan, Jan. 22, 2007, "Silent No Longer: Researchers Unearth another Stratum of Meaning in the Genetic Code," Chemical and Engineering News, 85(4):38-40.6Apeler, H. et al., Aug. 1, 1997, "Expression of Natural and Synthetic Genes Encoding Herpes Simplex Virus 1 Protease in Escherichia coli and Purification of the Protein," European Journal of Biochemistry, 247 (3):890-895, XP002318941, ISSN: 0014-2956.7Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Dec. 12, 2005.8Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Jun. 1, 2006.9Australian Examiner's Report for Sichuan Biotechnology Research Center, Australian Application No. 2004279350 Dated Mar. 1, 2010.10Australian Notice of Acceptance for Sichuan Biotechnology Research Center, Australian Application No. 2003248419, Filed Sep. 26, 2003, Dated Dec. 18, 2006.11Australian Office Action, Mar. 28, 2011, Guangwen Wei, Australian Application No. 2006257286, Filed Aug. 8, 2007.12Austrian Written Opinion, Jun. 29, 2009, Singapore Application No. 200706014-8, Guangwen Wei, filed Mar. 9, 2006.13Ausubel et al., Eds., 1999, Chapter Ten, "Analysis of Proteins," from Short Protocols in Molecular Biology, 4th ed., p. 10-1 to 10-8.14Bingfa et al., 2009, "Anti-Hepatitis B Virus Activity and Mechanisms of Recombinant Human Serum Albumin-Interferon-α-2b Fusion Protein in vitro and in vivo", Pharmacology, 83:323-332.15Blatt, L.M. et al., 1996, "The biological activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon," Journal of Interferon and Cytokine Research, 16(7):489-499.16Canadian Offica Action, May 10, 2011, Huiyangtech (USA), Inc, Canadian Application No. 2,535,982, Filed Feb. 15, 2006, corresponding to Int'l App'l No. PCT/US2004/028067, Filed Aug. 26, 2004.17Canadian Office Action, Apr. 21, 2008, for Sichuan Biotechnolgy Research Center, Canadian Application No. 2,439,503, Filed Aug. 27, 2003.18Canadian Office Action, Jun. 1, 2009, Sichuan Biotechnolgy Research Center, Canadian Application No. 2,439,503, Filed Aug. 27, 2003.19Canadian Office Action, Mar. 8, 2011, Sichuan Biotechnology Research Center, Canadian Application No. 2,439,503, Filed Aug. 27, 2003.20Cao, Hongpeng, and Tao, Peizhen, "Effect of Anti-HBV of 6 Drugs Include Lamividine," Natl. Med. J. China, 2001, 81(16):1004-1007.21Chinese Decision About Rejection, Nov. 12, 2004, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].22Chinese Decision About the Reexamination, Oct. 26, 2005, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].23Chinese Examination Report, Aug. 25, 2010, Huiyangtech(USA), Inc., Chinese Application No. 200680007733.1 ((With English summary), Filed Sep. 10, 2007.24Chinese Examination Report, Aug. 7, 2009, Huiyangtech(USA), Inc., Chinese Application No. 200480031909.8, Filed Apr. 28, 2006.25Chinese Examination Report, Feb. 20, 2009, Huiyangtech(USA), Inc., Chinese Application No. 200480031909.8, Filed Apr. 28, 2006.26Chinese Examination Report, Nov. 20, 2009, Huiyangtech(USA), Inc., Chinese Patent Application No. 200480031910.0, Filed Apr. 28, 2006.27Chinese Examination Report, Nov. 27, 2009, Huiyangtech(USA), Inc., Chinese Application No. 200680007733.1, Filed Sep. 10, 2007.28Chinese First Notification of Examination, Apr. 18, 2003, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].29Chinese First Office Action, Feb. 20, 2009, for Huiyangtech (USA), Inc., Chinese Application No. 200480031909.8, Filed Apr. 28, 2006.30Chinese First Office Action, Mar. 27, 2009, for Huiyangtech (USA), Inc., Chinese Application No. 200480031910.0, Filed Apr. 28, 2006.31Chinese First Office Action, May 22, 2009, for Guangwen Wei, Chinese Application No. 200680007733.1, Filed Sep. 10, 2007.32Chinese Fourth Notification of Examination, Jun. 4, 2004, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].33Chinese Notification of Patent for Invention, Oct. 26, 2005, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].34Chinese Second Notification of Examination, Oct. 17, 2003, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].35Chinese Third Notification of Examination, Jan. 2, 2004, for Sichuan Biological Research Center, Chinese Application No. 01104367.9, Filed Feb. 28, 2001. [with full English translation].36Cinatl et al., 2003, "Treatment of SARS with Human Interferons," The Lancet, 362:293-294.37Day et al., 1992, "Engineered Disulfide Bond Greatly Increases Specific Activity of Recombinant Murine Interferon-Beta," Journal of Interferon Res., 12:139-143.38Duan et al., 2003, "Anti-SARS virus activities of different recombinant human interferons in cell culture system," Chinese J. Clin. Virol., 17(3):205-208.39European Communication for Sichuan Biotechnology Research Center, European Application No. 02702211.0, Filed Sep. 25, 2003, Dated Dec. 14, 2006.40European Communication, Aug. 26, 2008, for Sichuan Biological Research Center, European Application No. 02702211.0, Filed Mar. 23, 2006.41European Communication, Jun. 19, 2006, for Sichuan Biological Research Center, European Application No. 02702211.0, Filed Mar. 23, 2006.42European Communication, Jun. 19, 2009, Sichuan Biotechnology Research Center, European App'l No. 02702211.0, Filed Sep. 25, 2003.43European Communication, Nov. 27, 2008, for Huiyangtech (USA), Inc., European Application No. EP 04782529.4, Filed Mar. 23, 2006.44European Communication, Nov. 28, 2008, for Huiyangtech (USA), Inc., European Application No. EP 04809634.1, Filed Mar. 23, 2006.45European Examiner's Report, Jan. 14, 2011, Sichuan Biotechnology Research Center, European Patent Application No. EP 04809634.1, Filed Mar. 23, 2006.46European Examiner's Report, Jul. 28, 2009, Huiyangtech(USA), Inc., European Application No. 04809634.1, Filed Mar. 26, 2006.47European Examiner's Report, Jul. 29, 2009, Huiyangtech(USA), Inc., European Application No. 04782529.4, Filed Mar. 23, 2006.48European Search Report for Huiyangtech (USA), Inc., Apr. 26, 2011, Application No. EP 10 19 3126.49Examiner's Report for Wei et al., European App'l No. 02702211.0, Filed Sep. 25, 2003, Dated Dec. 13, 2007.50Examiner's Written Opinion for Huiyangtech (USA), Inc., Singaporean App'l No. 200601209-0, Filed Feb. 23, 2006, Dated Jan. 8, 2008.51Fei et al., 1999, "Clinical Observation of Effect on Treatment of Chronic Hepatitis B by a Combination of Interferon and Lamividine," Shandong Medical Journal, 39(11):3-4.52Gao et al., 1999, "Treatment of Hepatitis Virus Related Pediatric Nephritis With IFN," Academic Journal Of Jinlin Hospital, 12(1):155-157.53Gao Zhan-Cheng et al., 2003, "Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome", Database Medline, Database accession No. NLM12837162.54Greenberg et al., Sep. 2, 1976, "Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis", 295(10):517-522. (abstract only).55Guzman, Luz-Maria et al, 1995, "Tight Regulation, Modulation, and High-Level Expression by Vectors Containing the Arabinose P-Bad Promoter," Journal of Bacteriology, 177(14):4121-4130, Xp002121022, ISSN: 0021-9193.56Heathcote, E.J.L. et al., 1998, "Re-treatment of chronic hepatitis C with consensus interferon," Hepatology 27(4):1136-1143.57Higgins et al., 1983, "Intranasal Interferon as Protection against Experimental Respiratory Coronavirus Infection in Volunteers," Antimicrobial Agents and Chemotherapy 24(5):713-715.58Holland, C.C. and T.L. Wright, "New approaches to treatment of chronic viral hepatitis," Pathology (Phila.), 1994: 3(1), Full Article.59Huang, Wanzhi et al., Jun. 72, 2000, "Use of the Arabinose pBAD Promoter for Tightly Regulated Display of Proteins on Bacteriophage," Gene (Amsterdam), 251(2):187-197, XP004206676, ISSN: 0378-1119.60Indian Examination Report for Sichuan Biotechnology Research Center, Indian Application No. 279/MUM/2004, Filed Mar. 5, 2004, Dated Aug. 2, 2007.61Indian Examination Report, Aug. 1, 2008, for Huiyangtech(USA), Inc., Indian Application No. 310/MUMUMP/2006, Filed Oct. 3, 2006.62Indian Examiner's Report, Aug. 20, 2009, Indian Application No. 00310/MUMNP/2006, Wei et al., Filed Oct. 17, 2007.63Indian Examiner's Report, May 10, 2010, Indian Application No. 1214/MUMNP/2007, Guangwen Wei, Filed Aug. 13, 2007.64Indian Examiner's Report, May 4, 2010, Indian Application No. 00311/MUMNP/2006, Huiyangtech (USA) Inc., Filed Mar. 24, 2006.65Indian Examiner's Report, Sep. 16, 2009, Indian Application No. 00311/MUMNP/2006, Huiyangtech (USA) Inc., Filed Mar. 24, 2006.66Indian Office Action, Oct. 24, 2008, for Sichuan Biological Research Center, Indian Patent Application No. 280/MUM/2004, Filed Mar. 5, 2004.67Indian patent for 279/MUM/2004, Jan. 28, 2009, Sichuan Biological Research Center.68Infergen (Interferon alfacon-1) Product Sheet, Amgen, Inc., Issue Date: Nov. 30, 1998.69International Preliminary Examination Report, Application No. PCT/CN02/00128 for Sichuan Biotechnology Research Center, "Recombination Super Compound Interferon Used as Hepatitis B Surface Antigen and E Antigen Inhibitor," Filed Feb. 28, 2002, Dated Feb. 15, 2004.70International Search Report, Application No. PCT/CN02/00128 for Sichuan Biotechnology Research Center, "Recombination Super Compound Interferon Used as Hepatitis B Surface Antigen and E Antigen Inhibitor," Filed Feb. 28, 2002, Dated Aug. 8, 2002, Date of Completion of the Search: Jul. 23, 2002.71International Search Report, Application No. PCT/US04/28068 for Huiyangtech (USA) Inc., Filed Aug. 26, 2004, Dated Mar. 4, 2005.72International Search Report, Application No. PCT/US2004/028067 for Huiyangtech, Inc., "Uses of interferons with altered spatial structure," Filed Aug. 26, 2004, Dated Feb. 27, 2006, Date of Completion of the Search: Nov. 2, 2005.73Japanese Examiner's Report, Dec. 2, 2009, Sichuan Biotechnology Research Center, Japanese Patent Application No. 2002-578997, Filed Aug. 28, 2003.74Japanese Examiner's Report, Dec. 28, 2010, Sichuan Biotechnology Research Center, Japanese Patent Application No. 2006-524916, Filed Feb. 27, 2006.75Japanese Examiner's Report, Jul. 26, 2010, Huiyangtech (USA), Inc., Japanese Patent Application No. 2006-524916, Filed Feb. 27, 2006 (with English summary).76Japanese Examiner's Report, May 10, 2010, Huiyangtech (USA), Inc., Japanese Patent Application No. 2006-524916, Filed Feb. 27, 2006.77Japanese Notification of Reasons of Refusal, Jun. 17, 2008, for Sichuan Biotechnology Research Center, Japanese Application No. 2002-578997, Filed Aug. 28, 2003. [with full English translation].78Klein, M.L. et al., 1998, "Structural character-ization of recombinant consensus interferon-alpha," Journal of Chromatography, 454:205-215.79Krogsgaard et al., 1996, "Relation Between efficacy and cumulative dose of alpha interferon in chronic hepatitis B. European Concerted Action on Viral Hepatitis (Eurohep)", J Hepatology, 25(6):795-802.80Lang et al., 2002, "Observation on Serology And Histology Of Patients With Chronic Hepatitis B After Interferon Treatment," Chin. J. Infect. Dis., 20(2): 97-100.81Lei et al., 1995, "Observation on Clinical Treatment of Chronic Hepatitis B by Purified Human Leucocyte Interferon," Chinese Journal Of Practical Internal Medicine, 15(3)155-157.82Li et al., 1999, "Antiviral effects of rhIFN-alpha 1 against seven influenza viruses", Acta. Pharmacol. Sin. 20(8):709-714.83Loufty et al., 2003, "Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome—A preliminary Study", JAMA, 290(24):3222-3228.84Malaysian Advisory Action, Mar. 8, 2007, Sichuan Biotechnology Research Center, Malaysian Patent Application No. PI 20033246, Filed Aug. 28, 2003.85Malaysian Examiner's Report for Sichuan Biotechnology Research Center, Malaysian Application No. PI 20033246, Filed Aug. 28, 2003, Dated Mar. 8, 2007.86Malaysian Office Action, Aug. 11, 2008, for Sichuan Biological Research Center, Malaysian Patent Application No. PI 20033246, Filed Aug. 28, 2003.87Malaysian Office Action, Jan. 16, 2009, for Sichuan Biological Research Center, Malaysian Patent Application No. PI 20033246, Filed Aug. 28, 2003.88Malaysian Office Action, Jul. 13, 2009, Guangwen Wei, Malaysian Patent Application No. PI 20061015, Filed Mar. 9, 2006.89Moore et al., 1995, "A Phase I Study of Intraperitoneal Interferon-α2b cis-Platinum plus Cyclophosphamide Chemotherapy in Patients with Untreated Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Pilot Study", Gynecologic Oncology, 59:267-272.90Nackley, A.G. et al., Dec. 22, 2006, "Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure," Science, 314:1930-1932.91Nasoff et al., 1999, "High-Level Expression of Human Genes in E. coli," Expression, 6(2):10-11.92Notice of Allowance and Fee(s) Due notice for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, dated Jul. 26, 2007.93Notice of Allowance for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Dec. 12, 2007.94Notice of Allowance for Wei et al., U.S. Appl. No. 10/928,956, filed Aug. 26, 2004, Dated Apr. 2, 2008.95Notification Concerning Transmittal of International Preliminary Report on Patentability (Chapter I of the Patent Cooperation Treaty) for PCT/IB2006/002340 for Guangwen Wei, Dated Sep. 20, 2007.96Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority for Guangwen Wei (International Search Report and Written Opinion included), Application No. PCT/IB2006/002340, Filed Mar. 9, 2006, Dated May 10, 2007.97Ozes, O.N. et al., 1992, "A comparison of interferon-con1 with natural recombinant interferons: antiviral, antiproliferative, and natural killer-inducing activities." J. Interferon Res., 12:55-59.98pBAD Expression System, "Tightly Controlled Bacterial Protein Expression," Invitrogen Corp. Publication, 2002.99PCT Notification of Transmittal of International Preliminary Report on Patentability for Huiyangtech (USA) Inc., International Application No. PCT/US04/28068, Filed Aug. 26, 2004, Dated May 13, 2005.100Pfeffer, L.M., 1997, "Biologic activity of natural and synthetic type 1 interferons," Seminars in Oncology, 24(3 suppl. 9):S9-63-S9-69.101Pyrc, K. et al., 2007, "Antiviral strategies against human coronaviruses," Infectious Disorders-Drug Targets, (7):59-66.102Pyrc, K. et al., 2007, "Antiviral strategies against human coronaviruses," Infectious Disorders—Drug Targets, (7):59-66.103Schulte-Frohlinde, et al., Feb. 21, 2002, "Different Activities of Type I interferons on Hepatitis B virus core promoter regulated transcription." Cytokine, 17(4): 214-220. [Cited by Examiner in Advisory Action of Mar. 18, 2008].104Singapore grant for 200304969, Nov. 30, 2005, Sichuan Biological Research Center.105Singapore grant for 200601204-1, Mar. 31, 2009, Huitangtech(USA), Inc.106Singapore Written Opinion for Huiyangtech (USA), Inc., Singapore Application No. 200601204-1, Filed Feb. 23, 2006, Dated Jul. 19, 2007.107Singapore Written Opinion, Apr. 29, 2008, for Huiyangtech (USA), Inc., Singapore Application No. 200601204-1, Filed Feb. 23, 2006.108Singapore Written Opinion, Mar. 26, 2010, Guangwen Wei, Singapore Application No. 200706014-8, Filed Aug. 15, 2007.109Spada S., 2004, "Infergen", Directory of Approved Biopharmaceutic. Prod., 116-117.110Supplementary European Search Report for Sichuan Biotechnology Research Center, Application No. EP 02702211, Filed Feb. 28, 2002, Date Of Completing Of The Search: Feb. 23, 2005.111Taiwanese Examination Report, Dec. 12, 2008, for Guangwen Wei, Taiwanese Application No. 95107930, Filed Mar. 9, 2006. [with full English translation].112Taiwanese Examiner's Report, Mar. 2010, Huiyangtech(USA), Inc., Taiwanese App'l No. 92,123,846, Filed Aug. 28, 2003.113Taiwanese Examiner's Report, May 25, 2009, Huiyangtech(USA), Inc., Taiwanese Application No. 095107930, Filed Mar. 9, 2006.114Taiwanese Formal Rejection for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Dec. 29, 2006.115Taiwanese Formal Rejection, Dec. 11, 2006, for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003. [with full English translation].116Taiwanese Office Action for Sichuan Biotechnology Research Center, Taiwanese Application No. 92,123,846, Filed Aug. 28, 2003, Dated Sep. 21, 2006.117U.S Office Action, Jun. 20, 2011, Guangwen Wei, U.S. Appl. No. 12/246,153, Filed Oct. 6, 2008.118U.S. Examiner's Answer to Appeal Brief, Dec. 9, 2008, for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004.119U.S. Final Office Action, Apr. 15, 2009, for Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004.120U.S. Notice of Allowance and Fee(s) Due, Jun. 25, 2008, for Guangwen Wei, U.S. Appl. No. 10/928,956, filed Aug. 26, 2004.121U.S. Notice of Allowance and Fee(s) Due, Sep. 22, 2008, for Guangwen Wei, U.S. Appl. No. 10/928,956, filed Aug. 26, 2004.122U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004, Dated Apr. 2, 2008.123U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004, Dated Apr. 3, 2007.124U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004, Dated Sep. 19, 2007.125U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated Aug. 22, 2006.126U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated Aug. 9, 2007.127U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated Feb. 9, 2007.128U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,474, filed Aug. 26, 2004, Dated Jan. 4, 2008.129U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,956, filed Aug. 26, 2004, Dated Dec. 15, 2006.130U.S. Office Action for Guangwen Wei, U.S. Appl. No. 10/928,956, filed Aug. 26, 2004, Dated Jun. 14, 2007.131U.S. Office Action for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005, Dated Aug. 1, 2007.132U.S. Office Action for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005, Dated Aug. 8, 2006.133U.S. Office Action for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005, Dated Feb. 6, 2008.134U.S. Office Action for Guangwen Wei, U.S. Appl. No. 11/077,813, filed Mar. 10, 2005, Dated Nov. 27, 2006.135U.S. Office Action for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Aug. 23, 2005.136U.S. Office Action for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Mar. 20, 2006.137U.S. Office Action for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Mar. 7, 2007.138U.S. Office Action for Wei et al., U.S. Appl. No. 10/650,365, filed Aug. 28, 2003, Dated Sep. 20, 2006.139U.S. Office Action, Apr. 15, 2010, for Guangwen Wei, U.S. Appl. No. 12/369,005, filed Feb. 11, 2009.140U.S. Office Action, Apr. 29, 2005, for Guangwen Wei, U.S. Appl. No. 10/650,365, Patent No. 7,364,724, filed Aug. 28, 2003.141U.S. Office Action, Aug. 2, 2010, Guangwen Wei, U.S. Appl. No. 12/369,005, Filed Feb. 11, 2009.142U.S. Office Action, Aug. 4, 2010, Guangwen Wei, U.S. Appl. No. 12/246,153, Filed Oct. 6, 2008.143U.S. Office Action, Aug. 8, 2006, for Guangwen Wei, U.S. Appl. No. 10/928,956, filed Aug. 26, 2004.144U.S. Office Action, Dec, 17, 2010, for Guangwen Wei, U.S. Appl. No. 12/246,153, Filed Oct. 6, 2008.145U.S. Office Action, Dec. 2, 2009 Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004.146U.S. Office Action, Dec. 22, 2010, for Guangwen Wei, U.S. Appl. No. 12/554,297, Filed Sep. 4, 2009.147U.S. Office Action, Feb. 23, 2009, for Guangwen Wei, U.S. Appl. No. 11/817,926, filed Sep. 6, 2007.148U.S. Office Action, Jan. 25, 2011, Guangwen Wei, U.S. Appl. No. 10/928,474, Filed Aug. 26, 2004.149U.S. Office Action, Jan. 6, 2010, Guangwen Wei, U.S. Appl. No. 12/246,153, filed Oct. 6, 2008.150U.S. Office Action, Jun. 14,2011, Guangwen Wei, U.S. Appl. No. 12/554,297, Filed Sep. 4, 2009.151U.S. Office Action, Jun. 23, 2009, Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004.152U.S. Office Action, Nov. 14, 2008, for Guangwen Wei, U.S. Appl. No. 10/927,975, filed Aug. 26, 2004.153U.S. Office Action, Sep. 29, 2009, Guangwen Wei, U.S. Appl. No. 11/817,926, filed Mar. 9, 2005.154U.S. Office Action, Sep. 30, 2009, Guangwen Wei, U.S. Appl. No. 12/369,005, filed Feb. 11, 2009.155Wang, C. et al., 2006, "Refolding Recombinant Human Granulocyte Colony Stimulating Factor Expressed by E. coli: A Case Study Using the Unit of Simultaneous Renaturation and Purification of Proteins," BioProcess International, 48-53.156Wang, Xiangye, and Li, Xuegang, 1994, "Comparing Effect of Three Drugs on Turning HBEAG to Negative," Qienwei Medical Journal, 11(4):197-198.157Wong, Samson S. Y. and Yuen, Kwok-Yung, 2008, "The management of coronavirus infections with particular reference to SARS", Journal of Antimicrobial Chemotherapy, 62:437-441.158Written Opinion for Huiyangtech (USA) Inc., International Searching Authority for PCT/US04/28068, Filed Aug. 26, 2004, Dated Mar. 4, 2005.159Written Opinion of the Australian Patent Office for SG 200601209-0, National Phase under Chapter II Based on PCT/US2004/028067 for Huiyangtech (USA) Inc., Dated Dec. 4, 2007.160Written Opinion of the International Searching Authority for PCT/US2004/028067, Dated Aug. 26, 2004 for Huiyangtech (USA) Inc., Dated Nov. 2, 2005.161Wu, et al., 2003, "A hospital outbreak of severe acute respiratory syndrome in Guangzhou, China." Chinese Medicine Journal, 116(6):811-818.162Yasuda, et al., 2000, "Spectrum of virus inhibition by consensus interferon YM643." Antiviral Chemistry & Chemotherapy, 11:337-341.163Zeng, Zheng et al., 2000, "Transfer and expression of human interferon-α and its effect on HBV inhibition," Chinese Journal of Infectious Disease, 18(4):221-224. [English abstract only].164Zhao, Z. et al., 2003, "Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China," Journal of Med. Microbiol. 52:715-720.165Zheng, B. et al., 2004, "Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma)," J. Interferon Cytokine Res., 24(7):288-90. [Abstract only].Classifications U.S. Classification424/85.7, 530/351, 435/69.51, 514/4.3International ClassificationA61P35/02, C12N15/09, A61P31/20, C12N15/20, C07K14/555, A61P1/16, A61P31/18, A61K38/21, A61P31/14, A61P31/22, A61P31/12, A61P31/16, C12N15/21, C07K14/56, A61K38/00Cooperative ClassificationC07K14/555, A61K38/00European ClassificationC07K14/555Legal EventsDateCodeEventDescriptionSep 3, 2008ASAssignmentOwner name: SICHUAN BIOTECHNOLOGY RESEARCH CENTER, CHINAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEI, GUANGWEN;GUO, RONGBING;ZHANG, RENHUAI;REEL/FRAME:021475/0115Effective date: 20030929Apr 22, 2014CCCertificate of correctionRotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services